Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics Limited has announced a change in the director’s interest notice for Dr. Christopher Burns, reflecting updates in his securities holdings. This announcement, authorized by the company’s secretary, highlights the ongoing management and regulatory compliance within the company, potentially impacting investor perceptions and stakeholder confidence.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic cancer and chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 74.16%
Average Trading Volume: 7,216,964
Technical Sentiment Signal: Hold
Current Market Cap: A$79.53M
For an in-depth examination of ATX stock, go to TipRanks’ Overview page.